Acute Psychotic Episode (Adult)

Topic Overview

Summary

An acute psychotic episode is a psychiatric emergency characterized by loss of contact with reality, manifesting as hallucinations, delusions, disorganized speech/behavior, and negative symptoms. First-episode psychosis (FEP) requires urgent medical and psychiatric evaluation to exclude organic causes (delirium, encephalitis, substance intoxication, metabolic disturbances), establish a provisional diagnosis (schizophrenia, brief psychotic disorder, schizoaffective disorder, drug-induced psychosis), initiate antipsychotic medication, conduct comprehensive risk assessment, and arrange early intervention services. Duration of untreated psychosis (DUP) is a critical prognostic factor—shorter DUP correlates with better long-term outcomes.

Key Facts

• Prevalence: Lifetime risk of psychotic disorder ~3%; schizophrenia ~1%
• Peak onset: Late adolescence to early 30s (males 18-25, females 25-35)
• Positive symptoms: Hallucinations (auditory most common), delusions, disorganized speech/behavior
• Negative symptoms: Flat affect, alogia, avolition, anhedonia, social withdrawal
• Critical intervention: DUP less than 3 months associated with better outcomes
• First-line antipsychotics: Risperidone, olanzapine, aripiprazole (avoid haloperidol as first-line in FEP)
• Organic causes: Must exclude delirium, substance intoxication/withdrawal, autoimmune encephalitis, brain lesions

Clinical Pearls

Duration of Untreated Psychosis (DUP) is one of the most robust prognostic factors—every month of delay worsens functional outcomes. Urgent psychiatric referral is mandatory.

Exclude organic causes systematically: Delirium presents with fluctuating consciousness and inattention; psychosis alone does not impair consciousness. Red flags include acute confusion, fever, focal neurology, or recent substance use.

Command hallucinations require direct inquiry—ask "Do the voices tell you to do things? To hurt yourself or others?" This guides immediate risk management.

Avoid high-potency typical antipsychotics (haloperidol) as first-line in first-episode psychosis—higher risk of extrapyramidal side effects (EPS) and poor adherence.

Why This Matters Clinically

Acute psychotic episodes are psychiatric emergencies with profound implications for patient safety, long-term functioning, and quality of life. Early intervention reduces DUP, improves symptom remission rates, enhances social/occupational recovery, and reduces suicide risk (10-15% lifetime in schizophrenia). Missed organic causes (e.g., anti-NMDA receptor encephalitis) can be fatal if untreated. Mental Health Act assessments may be required to ensure treatment when patients lack capacity or pose risks.

---

Visual Summary

Visual assets to be added:

• Algorithm: Acute psychosis assessment and management pathway
• Table: Positive vs negative symptoms with clinical examples
• Flowchart: Differential diagnosis of first-episode psychosis
• Infographic: Early Intervention in Psychosis (EIP) service pathway
• Timeline: Critical intervention windows and DUP impact

---

Clinical Vignettes

Case 1: Classic First-Episode Psychosis

Presentation: A 22-year-old male university student is brought to the Emergency Department by concerned flatmates. Over the past 3 weeks, he has become increasingly withdrawn, stopped attending lectures, and spent hours alone in his room. He believes that his mobile phone is being used by MI5 to monitor his thoughts and that messages on social media contain coded instructions meant specifically for him. He hears multiple voices commenting on his actions, saying "he's going to the kitchen now" and "he doesn't know we're watching." He has stopped eating, fearing his food is poisoned. Last night, he barricaded himself in his room and threatened flatmates who tried to check on him.

Clinical Assessment:

• Positive symptoms: Persecutory delusions (MI5 monitoring), delusions of reference (social media messages), third-person auditory hallucinations (running commentary), paranoid ideation (poisoned food)
• Negative symptoms: Social withdrawal, self-neglect
• Risk: Potential for aggression (threatened flatmates), vulnerability (not eating), possible command hallucinations
• Duration: 3 weeks of active symptoms; prodromal phase unclear

Immediate Management:

1. Safety: Low-stimulus environment, de-escalation, staff vigilance
2. Medical workup: FBC, U&E, TFTs, glucose, calcium, B12, syphilis serology, HIV, urine drug screen (cannabis?), ECG
3. Risk assessment: Explore suicidal ideation, command hallucinations, intent to harm others
4. Mental Health Act assessment: Likely lacks capacity to consent to treatment; appears to pose risk to others and self (vulnerability); Section 2 probable
5. Antipsychotic: Start risperidone 2mg or olanzapine 10mg (oral if accepts; IM if refuses)
6. Urgent psychiatry referral: EIP service assessment

Differential Diagnosis:

• Schizophrenia (most likely if symptoms persist > 1 month)
• Brief psychotic disorder (if symptoms resolve within 1 month)
• Cannabis-induced psychotic disorder (check drug screen; ask about recent use)
• Organic causes: Less likely given age and gradual onset, but must exclude

Outcome: Drug screen positive for cannabis. Symptoms improve significantly on risperidone 3mg over 2 weeks but do not fully resolve. Diagnosed with schizophrenia at 6-month review. Engages with EIP service; returns to university part-time.

---

Case 2: Drug-Induced Psychosis vs. Primary Disorder

Presentation: A 27-year-old woman presents with 48 hours of bizarre behavior following a music festival. She believes she is "connected to the universe" and can "communicate telepathically with strangers." She hears angelic voices telling her she has a "divine mission." She has not slept for 3 days, is agitated, and attempts to leave the department to "spread her message." Friends report she took "ecstasy" and possibly other substances at the festival. No prior psychiatric history.

Clinical Assessment:

• Positive symptoms: Grandiose delusions (divine mission), auditory hallucinations (angelic voices), thought broadcasting
• Acute onset: 48 hours, clearly temporally related to substance use
• Psychomotor: Agitated, pressured speech, decreased need for sleep (manic features)
• Risk: Impulsive behavior, vulnerability, potential for self-harm (e.g., jumping from height believing she can fly)

Immediate Management:

1. Safety: Constant observation, prevent absconding
2. Medical workup: Urine drug screen (MDMA, amphetamines, cocaine, synthetic cannabinoids), ECG (MDMA can cause arrhythmias, hyponatremia), U&E (hyponatremia from water intoxication), creatine kinase (rhabdomyolysis)
3. Supportive care: IV fluids, benzodiazepine (lorazepam 1-2mg) for agitation
4. Antipsychotic: Haloperidol 5mg IM or olanzapine 10mg IM if severe agitation unresponsive to benzodiazepine
5. Monitor: Temperature (serotonin syndrome, hyperthermia from MDMA), electrolytes

Differential Diagnosis:

• Substance-induced psychotic disorder (most likely—acute onset, temporally related to drug use)
• Brief psychotic disorder (if symptoms persist beyond acute intoxication but less than 1 month)
• Bipolar disorder, manic episode (grandiosity, decreased sleep, agitation—but first episode at 27 after drug use)
• Schizoaffective disorder (less likely without prior history)

Outcome: Urine positive for MDMA, cocaine. Symptoms resolve completely within 5 days of abstinence and supportive care. No antipsychotic required beyond acute phase. Diagnosis: Substance-induced psychotic disorder. Close follow-up recommended to monitor for recurrence or emergence of primary disorder.

---

Case 3: Late-Onset Psychosis with Organic Cause

Presentation: A 58-year-old woman with no psychiatric history presents with 2 weeks of progressive behavioral change. She accuses her husband of infidelity (he denies; married 30 years), believes neighbors are spying through the walls, and hears voices insulting her. She has become disinhibited (undressing in front of windows), has episodes of staring and lip-smacking lasting 20-30 seconds, and has developed urinary incontinence. She is confused about recent events but recognizes family. Examination: mild fever (37.8°C), occasional myoclonic jerks.

Clinical Assessment:

• Red flags: Late onset (58 years), acute/subacute progression (2 weeks), fever, seizure-like episodes (automatisms), cognitive impairment (confusion), myoclonus
• This is NOT primary psychosis: Organic cause highly likely

Immediate Management:

1. Urgent investigations:
   • MRI brain: Rule out tumor, encephalitis, stroke
   • EEG: Seizure activity? (Automatisms suggest temporal lobe involvement)
   • Lumbar puncture: CSF analysis (WCC, protein, glucose, oligoclonal bands, HSV PCR, autoimmune encephalitis panel)
   • Autoimmune screen: Anti-NMDA receptor antibodies, anti-LGI1, anti-VGKC, anti-GAD
   • Bloods: FBC, U&E, LFTs, TFTs, glucose, calcium, B12, HIV, syphilis, paraneoplastic antibodies
2. Empirical treatment: IV aciclovir (herpes simplex encephalitis—cannot wait for LP/PCR) + supportive care
3. Antipsychotic: Use cautiously (may lower seizure threshold); prioritize treating underlying cause
4. Neurology/psychiatry liaison: Urgent co-management

Differential Diagnosis:

• Autoimmune encephalitis (anti-NMDA receptor most likely—psychiatric symptoms, seizures, movement disorder) [10]
• Herpes simplex encephalitis (fever, behavioral change, temporal lobe involvement)
• Paraneoplastic syndrome (age > 50, consider ovarian teratoma with anti-NMDA receptor)
• Frontotemporal dementia (behavioral disinhibition, but seizures less typical)
• Delirium (fluctuating cognition, but prominent psychosis over 2 weeks less typical)

Outcome: CSF: lymphocytic pleocytosis, elevated protein. Serum anti-NMDA receptor antibodies positive. MRI: subtle T2 hyperintensity in medial temporal lobes. Diagnosis: Anti-NMDA receptor encephalitis. CT chest/abdomen/pelvis: ovarian teratoma identified. Treatment: IV immunoglobulin, oophorectomy. Symptoms resolve over 6 weeks. Complete recovery.

Learning point: Late-onset psychosis, especially with fever, seizures, movement disorder, or rapid cognitive decline, mandates urgent investigation for autoimmune/infectious encephalitis. Delayed diagnosis is life-threatening.

---

Case 4: Postpartum Psychosis

Presentation: A 32-year-old woman, 10 days postpartum (first baby), presents with 48 hours of insomnia, agitation, and bizarre beliefs. She believes her baby is "possessed" and "not really hers," hears voices telling her to "protect the baby from evil," and has attempted to perform a "cleansing ritual" involving water. She is distractible, has rapid pressured speech, and exhibits labile mood (euphoric then tearful). No prior psychiatric history. Family history: mother has bipolar disorder.

Clinical Assessment:

• Psychiatric emergency: Postpartum psychosis (onset within 2 weeks postpartum)
• Risk: Infanticide (rare but devastating—5% of postpartum psychosis), suicide (5%), impaired judgment endangering infant
• Symptoms: Delusions (baby possessed), auditory hallucinations (command to protect), manic features (pressured speech, labile mood, insomnia)
• Family history: Bipolar disorder (20-30% risk of postpartum psychosis in women with bipolar)

Immediate Management:

1. Safety: Do not separate mother and baby unless absolutely necessary (increases distress, risk of severe depression), but ensure constant supervision (ideally Mother and Baby Unit)
2. Urgent psychiatry referral: Specialist perinatal mental health service
3. Admission: Psychiatric inpatient unit, preferably Mother and Baby Unit (allows mother-infant bonding under supervision)
4. Risk assessment: Direct questions about thoughts of harming baby or self
5. Medication:
   • Antipsychotic: Olanzapine 10mg or quetiapine 100mg (safest in breastfeeding)
   • Mood stabilizer: Consider lithium or valproate if bipolar suspected (but caution with breastfeeding)
   • Benzodiazepine: Lorazepam 1-2mg for acute agitation/insomnia
6. Supportive care: Involve partner/family, ensure infant feeding (breastfeeding compatible with most antipsychotics; formula if needed)

Differential Diagnosis:

• Postpartum psychosis (most likely—acute onset within 2 weeks, manic features, family history of bipolar)
• Brief psychotic disorder (temporally related to stressor of childbirth)
• Bipolar disorder, manic episode (may be first presentation triggered by postpartum)
• Organic causes: Eclampsia (if late postpartum, but usually peripartum), autoimmune encephalitis (rare), thyroiditis (can cause mood symptoms)

Outcome: Admitted to Mother and Baby Unit under Section 2 (lacked capacity, risk to infant). Treated with olanzapine 15mg, lorazepam PRN. Symptoms resolved over 10 days. Continued olanzapine for 6 months, then tapered. Diagnosed with bipolar disorder (postpartum psychosis is often first presentation). Prophylactic lithium recommended for future pregnancies.

Learning point: Postpartum psychosis is a psychiatric emergency with high risk of infanticide and suicide. Admit to Mother and Baby Unit if possible; keep mother and baby together under supervision. Treat aggressively with antipsychotic ± mood stabilizer.

---

Epidemiology

Incidence and Prevalence

• Psychotic disorders (all causes): Lifetime prevalence ~3%
• Schizophrenia: Lifetime prevalence 0.7-1.0%; annual incidence 15-20 per 100,000 [1]
• First-episode psychosis: Annual incidence ~50 per 100,000 in at-risk age groups (15-35 years) [2]
• Brief psychotic disorder: Less common; accounts for ~10% of first-episode cases
• Schizoaffective disorder: Prevalence ~0.3%; intermediate between schizophrenia and mood disorders [3]

Demographics

• Age of onset:
  • "Males: Peak 18-25 years (earlier onset, worse prognosis)"
  • "Females: Peak 25-35 years (second peak in perimenopause)"
• Sex: Schizophrenia affects males and females equally; males have earlier onset and more negative symptoms
• Ethnicity: Higher incidence in urban settings, migrant populations, Black Caribbean and African communities in UK [4]
• Socioeconomic: Increased incidence in lower socioeconomic groups, social drift hypothesis

Risk Factors

---

Pathophysiology

Neurotransmitter Hypotheses

Dopamine Hypothesis:

• Mesolimbic pathway hyperactivity → positive symptoms (hallucinations, delusions)
• Supported by efficacy of dopamine D2 receptor antagonists (antipsychotics)
• PET studies demonstrate increased presynaptic dopamine synthesis in striatum [7]

Mesocortical pathway hypoactivity → negative symptoms and cognitive deficits

• Reduced prefrontal dopamine contributes to executive dysfunction

Glutamate Hypothesis:

• NMDA receptor hypofunction on GABAergic interneurons → disinhibition of glutamate release
• Explains effects of NMDA antagonists (ketamine, PCP) producing psychosis-like states
• Basis for emerging glutamatergic treatments [8]

Serotonin (5-HT2A):

• Hallucinogenic drugs (LSD, psilocybin) act as 5-HT2A agonists
• Atypical antipsychotics block 5-HT2A receptors

Structural and Functional Abnormalities

• Ventricular enlargement: Lateral ventricles enlarged in chronic schizophrenia
• Gray matter reduction: Prefrontal cortex, temporal lobes, hippocampus [9]
• White matter abnormalities: Reduced fractional anisotropy in frontotemporal tracts
• Progressive changes: Some patients show continued gray matter loss after illness onset (neuroprogression hypothesis)

Inflammatory and Immune Mechanisms

• Elevated pro-inflammatory cytokines (IL-6, TNF-α) in subsets of patients
• Microglial activation demonstrated in PET studies
• Autoimmune encephalitis (anti-NMDA receptor, anti-LGI1) can mimic primary psychosis [10]

---

Clinical Presentation

Positive Symptoms

Hallucinations:

• Auditory (most common): Third-person commentary, running commentary on actions, command hallucinations
• Visual: Less common in primary psychosis; suggest organic cause if prominent
• Tactile, olfactory, gustatory: Rare; consider organic etiology (e.g., temporal lobe epilepsy)

Delusions:

• Persecutory (most common): Belief of being followed, monitored, or targeted
• Grandiose: Inflated sense of power, knowledge, or identity
• Referential: Belief that environmental cues have special personal significance (TV, radio messages)
• Somatic: False beliefs about bodily functions or appearance
• Thought insertion/withdrawal/broadcasting: Schneiderian first-rank symptoms

Disorganized Speech:

• Formal thought disorder: Loosening of associations, tangentiality, derailment
• Neologisms: Invented words
• Word salad: Incoherent speech in severe cases

Disorganized or Catatonic Behavior:

• Unpredictable agitation, inappropriate affect
• Catatonia: Stupor, mutism, posturing, waxy flexibility, echolalia (psychiatric emergency)

Negative Symptoms

Negative symptoms often emerge insidiously before positive symptoms (prodromal phase) and persist during remission, contributing to functional impairment.

Cognitive Symptoms

• Executive dysfunction: Planning, problem-solving, cognitive flexibility
• Working memory deficits: Difficulty holding and manipulating information
• Attention and processing speed: Impaired sustained attention
• Cognitive deficits are core features, present from illness onset, and major determinants of functional outcomes [11]

Prodromal Phase

• Duration: Weeks to years before first psychotic episode
• Features: Social withdrawal, declining academic/occupational functioning, odd beliefs, perceptual disturbances, sleep disturbance, depression, anxiety
• At-Risk Mental State (ARMS): Attenuated psychotic symptoms without full-threshold psychosis; 20-30% transition to psychosis within 2 years [12]

Schneiderian First-Rank Symptoms

Kurt Schneider (1959) described symptoms he considered highly suggestive of schizophrenia. While no longer considered pathognomonic (can occur in other psychotic disorders, mood disorders with psychosis, and organic conditions), they remain clinically useful:

Clinical utility: Presence of first-rank symptoms in the context of clear consciousness supports a diagnosis of schizophrenia spectrum disorder, but their absence does not exclude it.

---

Differential Diagnosis

Primary Psychotic Disorders

Substance-Induced Psychotic Disorder

• Substances: Cannabis, amphetamines, cocaine, synthetic cannabinoids, hallucinogens, alcohol withdrawal, benzodiazepine withdrawal
• Cannabis-induced psychosis: Dose-dependent risk; high-potency cannabis (high THC:CBD ratio) increases risk 5-fold; persistent use after FEP worsens outcomes [6]
• Diagnostic criteria: Psychosis develops during or within 1 month of substance intoxication/withdrawal; symptoms exceed those typically associated with intoxication
• Clinical clue: Symptom resolution within days to weeks of abstinence favors substance-induced disorder

Psychotic Disorder Due to Another Medical Condition (Organic Psychosis)

Neurological:

• Delirium: Fluctuating consciousness, inattention, acute onset—most common psychiatric presentation in medical/surgical wards
• Autoimmune encephalitis: Anti-NMDA receptor encephalitis (young women, behavioral changes, seizures, dyskinesias, autonomic instability) [10]
• Temporal lobe epilepsy: Olfactory hallucinations, déjà vu, automatisms
• Brain tumors: Frontal or temporal lobe lesions
• Dementia: Alzheimer's disease, Lewy body dementia (visual hallucinations characteristic)
• CNS infections: Herpes encephalitis, HIV encephalopathy, neurosyphilis, tuberculous meningitis

Endocrine:

• Thyroid disorders: Hyperthyroidism, hypothyroidism (myxedema madness)
• Cushing's syndrome
• Addison's disease

Metabolic:

• Hypoglycemia, hyperglycemia
• Hyponatremia, hypercalcemia
• Hepatic encephalopathy
• Uremia
• Vitamin deficiencies: B12, thiamine (Wernicke-Korsakoff syndrome)

Other:

• Systemic lupus erythematosus (SLE): CNS lupus with psychosis
• Porphyria

Mood Disorders with Psychotic Features

• Major Depressive Disorder with psychotic features: Mood-congruent delusions (guilt, worthlessness, nihilism)
• Bipolar Disorder (manic episode) with psychotic features: Grandiose delusions, mood-congruent hallucinations

---

Investigations

Mental State Examination (MSE)

Mental State Examination (MSE):

• Appearance and behavior: Grooming, agitation, eye contact, rapport
• Speech: Rate, volume, coherence
• Mood and affect: Subjective mood, objective affect (congruence, range, appropriateness)
• Thought form and content: Formal thought disorder, delusions (type, systematization, conviction)
• Perception: Hallucinations (modality, content, second-person vs third-person)
• Cognition: Orientation, attention, memory (screen for delirium)
• Insight and judgment: Awareness of illness, treatment acceptance

Detailed MSE Components for Psychosis Assessment:

1. Appearance and Behavior:

• Self-care: Unkempt, poor hygiene (negative symptoms, self-neglect)
• Psychomotor activity: Agitation, retardation, catatonic features (posturing, waxy flexibility, echolalia)
• Eye contact: Poor eye contact common in psychosis (paranoia, social withdrawal)
• Rapport: Difficult to establish if paranoid or disorganized

2. Speech:

• Rate: Pressured (mania), slow (depression, negative symptoms)
• Volume: Loud (responding to internal stimuli), whispered (paranoia)
• Coherence: Formal thought disorder (loosening of associations, tangentiality, derailment, word salad)

3. Mood and Affect:

• Subjective mood: Ask "How are you feeling?" (may be unable to articulate if severe)
• Objective affect:
  • "Flat/blunted: Reduced range of emotional expression (negative symptom, common in schizophrenia)"
  • "Inappropriate: Laughing when discussing distressing topics (incongruence)"
  • "Labile: Rapid shifts (suggests mania or organic cause)"

4. Thought Form:

• Formal thought disorder: Assess by listening to spontaneous speech or asking open-ended questions ("Tell me about your day")
  • "Tangentiality: Answers veer off-topic"
  • "Circumstantiality: Excessive unnecessary detail before reaching point"
  • "Loosening of associations (derailment): Jump between unrelated topics without logical connection"
  • "Flight of ideas: Rapid shifts driven by superficial associations (rhyming, punning)—suggests mania"
  • "Thought blocking: Sudden stop mid-sentence, unable to continue"
  • "Neologisms: Invented words"
  • Word salad: Completely incoherent speech ("The tree blue yesterday swimming pencil")

5. Thought Content:

• Delusions: Fixed false beliefs not amenable to change despite contrary evidence, not culturally sanctioned
  • "Assess for:"
    • Persecutory: "Do you feel unsafe? Is anyone trying to harm you?"
    • Grandiose: "Do you have special powers or abilities?"
    • Referential: "Do you notice things on TV or radio that seem meant for you?"
    • Control/passivity: "Do you feel in control of your thoughts and actions?"
    • Nihilistic: "Do you feel that parts of your body don't exist or are dead?" (Cotard's syndrome)
    • Somatic: "Is there something wrong with your body that doctors can't find?"
  • "Degree of systematization: Simple isolated delusion vs. complex delusional system"
  • "Degree of conviction: Unshakeable vs. some doubt"
  • "Bizarre vs. non-bizarre: Bizarre delusions are implausible (alien abduction); non-bizarre are plausible but false (spouse infidelity without evidence)"

6. Perception:

• Hallucinations: Perception in absence of external stimulus
  • Auditory: "Do you hear sounds or voices when no one is around?"
    • Second-person: "You are worthless" (more common in depression with psychosis)
    • Third-person: "He's going to hurt someone" (Schneiderian first-rank)
    • Running commentary: "She's walking to the door now" (Schneiderian first-rank)
    • Command hallucinations: "Do the voices tell you to do things? To hurt yourself or others?" (Critical to assess risk)
  • Visual: "Do you see things others don't see?" (Less common in primary psychosis; consider organic cause, e.g., delirium, Lewy body dementia)
  • Tactile: "Do you feel strange sensations on your skin?" (Formication—sensation of insects crawling on skin—consider cocaine use, delirium)
  • Olfactory: "Do you smell things others don't?" (Consider temporal lobe epilepsy, brain tumor)
  • Gustatory: "Do you notice unusual tastes?" (Rare; organic causes)
  • "Distinguish from:"
    • Illusions: Misinterpretation of real stimulus (seeing a coat rack as a person in dim light)
    • Pseudohallucinations: Experienced as inside the mind (less pathological; can be normal)

7. Cognition (Screen for Delirium):

• Consciousness: Alert vs. drowsy/fluctuating (fluctuating suggests delirium, NOT primary psychosis)
• Orientation: Person, place, time (disorientation suggests organic cause)
• Attention: "Count backward from 20" or "Spell WORLD backward" (impaired attention = delirium)
• Memory: Immediate recall ("Repeat these three words: apple, table, penny"), delayed recall (5 minutes later)—impaired suggests organic cause or dementia

8. Insight and Judgment:

• Awareness of illness: "Do you think there's anything wrong?" "Do you think you're unwell?"
• Attribution: "What do you think is causing these experiences?"
• Treatment acceptance: "Do you think you need help? Would you take medication?"
• Insight levels:
  • No insight: "I'm not ill; the voices are real"
  • Partial insight: "Maybe I'm unwell, but the government really is watching me"
  • Good insight: "I know these voices aren't real and are due to illness"

9. Risk Assessment (Integrated into MSE):

• Suicidal ideation: "Have you thought about harming yourself or ending your life? Do you have a plan?"
• Homicidal ideation: "Have you thought about harming anyone else? Do the voices tell you to hurt others?"
• Risk to self: Self-neglect, vulnerability to exploitation, impulsive behavior
• Risk to others: Paranoid delusions with identified persecutors, command hallucinations, past violence, substance use

---

Structured Risk Assessment Tools

For suicide risk:

• SAD PERSONS Scale: Sex (male), Age (less than 19 or > 45), Depression, Previous attempt, Ethanol/drug use, Rational thinking loss (psychosis), Social support lacking, Organized plan, No spouse, Sickness (chronic illness)
• Columbia-Suicide Severity Rating Scale (C-SSRS): Assesses ideation, intent, plan, behavior

For violence risk:

• HCR-20 (Historical, Clinical, Risk Management): 20-item structured professional judgment tool; historical (past violence, substance use), clinical (current symptoms, insight), risk management (future plans, treatment adherence)
• Clinical factors associated with violence:
  • "Delusions: Threat/control-override symptoms (belief of being threatened or controlled increases violence risk 2-3 fold)"
  • "Command hallucinations: Especially to harm identified person"
  • "Comorbid substance use: Increases risk substantially"
  • "Past violence: Strongest predictor of future violence"
  • Male sex, young age, antisocial traits

Protective factors (reduce risk):

• Strong social support, engagement with treatment, good therapeutic alliance, stable housing, employment/meaningful activity, absence of substance use

Immediate safety measures if high risk:

• Constant observation (1:1 nursing or seclusion if violent)
• Remove potential weapons (belts, shoelaces, sharp objects)
• Rapid tranquilization if severely agitated
• Mental Health Act assessment if lacks capacity and poses risk

---

Management

Immediate Management (Emergency Department / Acute Setting)

Safety and De-escalation:

1. Environmental modifications: Calm, low-stimulus environment; remove potential weapons
2. Verbal de-escalation: Non-confrontational, respectful communication; acknowledge distress without validating delusions
3. Offer oral medication before resorting to coercion
4. Restraint and rapid tranquilization only if imminent risk to self or others (see below)

Rapid Tranquilization (if required):

• Indication: Severe agitation, violence, risk to self/others unresponsive to de-escalation
• First-line oral: Lorazepam 1-2mg PO + antipsychotic (risperidone 1-2mg or olanzapine 5-10mg)
• Intramuscular (if oral refused/not feasible):
  • Lorazepam 1-2mg IM + haloperidol 5mg IM OR
  • Olanzapine 10mg IM (avoid combining with IM benzodiazepine—risk of respiratory depression)
  • Promethazine 50mg IM (if benzodiazepine/antipsychotic alone insufficient)
• Monitoring: Vital signs (BP, HR, RR, oxygen saturation) every 15 minutes for first hour, then hourly [15]
• Caution: Avoid excessive sedation (respiratory depression); have flumazenil available

Antipsychotic Medication

First-Line Antipsychotics for First-Episode Psychosis:

Avoid as first-line in FEP:

• Haloperidol and other typical antipsychotics: Higher EPS risk, poor adherence, worse subjective tolerability [16]

Clozapine:

• Indication: Treatment-resistant schizophrenia (failure of ≥2 adequate trials of different antipsychotics)
• Most effective antipsychotic; reduces suicide risk [17]
• Requires monitoring: Weekly FBC for 18 weeks, then fortnightly until 1 year, then monthly (risk of agranulocytosis 0.8%)
• Side effects: Sedation, hypersalivation, weight gain, metabolic syndrome, constipation (can be severe), myocarditis (rare but serious)

Principles of Antipsychotic Use:

• Start low, go slow: Minimize side effects, improve adherence
• Monotherapy preferred: Avoid polypharmacy unless treatment-resistant
• Adequate trial: 4-6 weeks at therapeutic dose before considering change
• Long-acting injectable (LAI): Consider if adherence concerns; improves relapse prevention [18]

Comprehensive Antipsychotic Comparison Table:

Receptor abbreviations: D2 (dopamine), 5-HT2A (serotonin), H1 (histamine—sedation, weight gain), M1 (muscarinic—anticholinergic effects), α1 (alpha-adrenergic—orthostatic hypotension)

---

Long-Acting Injectable (LAI) Antipsychotics

Advantages:

• Improved adherence: Eliminates need for daily oral medication
• Reduced relapse: Meta-analyses show 30% reduction in relapse vs. oral [18]
• Early detection of non-adherence: Missed depot appointment is visible (vs. hidden non-adherence with oral)
• Reduced stigma: Some patients prefer monthly injection over daily reminder of illness

Disadvantages:

• Requires patient consent (in UK, cannot give LAI under common law in emergency; requires Mental Health Act or capacity-based consent)
• Side effects persist longer if intolerable
• Injection site reactions (pain, nodules)
• Perceived as coercive by some patients

Available LAI antipsychotics:

When to consider LAI:

• History of relapse due to non-adherence
• Patient preference (some find monthly injection easier than daily tablets)
• Lack of insight (under Mental Health Act)
• Frequent relapses despite apparent adherence (check plasma levels if available)

---

Prognosis and Outcomes

Short-Term Outcomes (1 Year)

• Symptomatic remission: 40-50% achieve remission of positive symptoms with treatment [22]
• Relapse: 20-30% relapse within 1 year, often due to medication non-adherence

Long-Term Outcomes (5-10 Years)

• Recovery (symptomatic + functional): ~20-30% achieve full recovery
• Partial recovery: ~30-40% improved but residual symptoms or functional impairment
• Poor outcome: ~20-30% severe persistent symptoms, minimal functioning
• Suicide: Lifetime risk 10-15%; highest in first few years after diagnosis [14]

Prognostic Factors

Functional Outcomes

• Employment: 10-20% of individuals with schizophrenia competitively employed
• Independent living: Many require supported housing or live with family
• Cognitive deficits are primary drivers of functional impairment (more than positive symptoms)

---

Prevention and Early Detection

Primary Prevention (Reduce Incidence)

• Cannabis avoidance in adolescence/high-risk individuals
• Reduce obstetric complications: Adequate prenatal care
• Address childhood trauma: Early intervention for abuse/neglect

Secondary Prevention (Reduce DUP, Improve Outcomes)

• At-Risk Mental State (ARMS) clinics: Monitor individuals with attenuated psychotic symptoms
• Community education: Increase awareness of early warning signs (social withdrawal, academic decline, odd beliefs)
• Rapid-access pathways: Early Intervention in Psychosis services accept referrals from primary care, schools, self-referral

Relapse Prevention

• Medication adherence: Psychoeducation, long-acting injectables, adherence support
• Early warning signs: Teach patients/families to recognize prodromal symptoms (sleep disturbance, anxiety, social withdrawal)
• Avoid substance use: Cannabis, stimulants increase relapse risk 2-3 fold
• Stress management: CBT, social support, structured activities
• Regular follow-up: Community Mental Health Team (CMHT) or EIP services

---

Special Populations

Adolescents

• Diagnostic challenges: Distinguish from typical adolescent behavior, neurodevelopmental disorders (autism spectrum disorder)
• Early-onset schizophrenia (less than 18 years): More severe, worse prognosis, stronger genetic loading
• Cannabis use: Particularly harmful in adolescence (neurodevelopmental vulnerability)

Older Adults (Late-Onset Psychosis)

• Age > 40 (late-onset), > 60 (very-late-onset)
• Higher likelihood of organic causes: Dementia (Lewy body, Alzheimer's), delirium, brain lesions
• Sensory impairment: Visual/auditory impairment can contribute (Charles Bonnet syndrome)
• Treatment: Lower antipsychotic doses (increased sensitivity, medical comorbidities)

Pregnancy and Postpartum

• Postpartum psychosis: Psychiatric emergency; onset within 2 weeks postpartum; risk 1-2 per 1000 deliveries; higher risk in bipolar disorder (20-30%)
• Risk: Infanticide, suicide
• Management: Urgent psychiatric admission (ideally Mother and Baby Unit), antipsychotic ± mood stabilizer, do not separate mother and baby unless necessary
• Breastfeeding: Most antipsychotics compatible; olanzapine, quetiapine relatively safe

Comorbid Substance Use

• Prevalence: 50% of individuals with schizophrenia have substance use disorder [23]
• Cannabis: Most common; worsens symptoms, increases relapse, reduces treatment response
• Alcohol: Worsens adherence, increases depression/suicide risk
• Stimulants (cocaine, amphetamines): Can precipitate psychosis, exacerbate paranoia
• Integrated treatment: Address substance use and psychosis concurrently (not sequentially)

---

Treatment-Resistant Schizophrenia

Definition

Treatment resistance: Failure to respond adequately to ≥2 antipsychotics from different classes, each trialed at therapeutic dose for ≥6 weeks, with persistent moderate-severe symptoms.

Prevalence: ~30% of patients with schizophrenia are treatment-resistant.

Before Diagnosing Treatment Resistance: Checklist

1. Confirm adequate trials:

• Duration: ≥6 weeks at therapeutic dose (some guidelines suggest 8-12 weeks)
• Dose: Adequate (e.g., risperidone ≥4mg, olanzapine ≥15mg, aripiprazole ≥20mg)
• Different classes: Must trial antipsychotics with different receptor profiles

2. Assess adherence:

• Non-adherence is the most common cause of apparent treatment resistance
• Strategies:
  • Directly observed therapy
  • Plasma antipsychotic levels (if available)
  • Pill counts, pharmacy records
  • Consider switch to LAI

3. Exclude substance use:

• Ongoing cannabis, stimulant use sabotages treatment
• Urine drug screens

4. Exclude comorbid conditions worsening symptoms:

• Depression (negative symptoms may be depressive symptoms)
• Anxiety, PTSD (can exacerbate psychosis)
• Undiagnosed organic cause (e.g., temporal lobe epilepsy, autoimmune encephalitis)

5. Optimize psychosocial treatment:

• Engagement with CBTp, family intervention
• Address social stressors (housing, financial, relationships)
• Vocational support

Clozapine: Gold Standard for Treatment-Resistant Schizophrenia

Efficacy:

• 30-50% response rate in treatment-resistant patients (vs. 10-20% with other agents) [17]
• Only antipsychotic proven to reduce suicide risk (25% reduction vs. olanzapine)
• Reduces aggression, improves negative symptoms

Indications:

• Treatment-resistant schizophrenia (≥2 failed antipsychotic trials)
• High suicide risk in schizophrenia or schizoaffective disorder
• Severe aggression unresponsive to other antipsychotics

Contraindications:

• History of clozapine-induced agranulocytosis or myocarditis
• Bone marrow disorders (aplastic anemia, myeloproliferative disorders)
• Severe cardiac disease (uncontrolled heart failure, recent myocardial infarction)
• Alcoholic/toxic psychosis, drug intoxication, coma
• Uncontrolled epilepsy (lowers seizure threshold)

Initiation:

• Start 12.5mg once daily (evening, to minimize sedation)
• Titrate slowly: Increase by 12.5-25mg every 3-4 days
• Target dose: 300-450mg/day (divided BID or TDS)
• Max: 900mg/day (specialist supervision)

Monitoring Protocol:

Neutropenia/Agranulocytosis Management:

Side Effects (Common):

Side Effects (Serious but Rare):

Clozapine Augmentation Strategies (if partial response):

Note: Antipsychotic polypharmacy should be supervised by specialist and time-limited (review every 3-6 months).

---

Electroconvulsive Therapy (ECT) in Psychosis

Indications:

• Catatonia (first-line treatment; often more effective than benzodiazepines)
• Treatment-resistant schizophrenia (especially with affective symptoms; augmentation to clozapine)
• Schizoaffective disorder (depressive or manic type, severe)
• Acute psychotic episode with severe agitation/violence unresponsive to medication
• Pregnancy (when medication contraindicated/refused)

Efficacy:

• Catatonia: 80-90% response rate (dramatic, often after 1-2 sessions)
• Schizophrenia: 40-70% response (higher if affective symptoms, acute onset, shorter duration)
• Schizoaffective disorder: Similar to severe depression/mania

Protocol:

• Bilateral electrode placement (more effective for psychosis than unilateral)
• 2-3 sessions per week
• Acute course: 6-12 sessions (continue until plateau in improvement)
• Maintenance ECT: Consider if relapse after acute course (weekly to monthly)

Side effects:

• Cognitive impairment (retrograde/anterograde amnesia, usually temporary)
• Headache, muscle aches
• Cardiovascular (transient hypertension, bradycardia → tachycardia during seizure)
• Rare: Prolonged seizure, aspiration

Contraindications (relative):

• Raised intracranial pressure (space-occupying lesion, recent stroke)
• Recent myocardial infarction (less than 3 months), unstable angina
• Pheochromocytoma, uncontrolled hypertension

---

Catatonia: Recognition and Management

Definition: Psychomotor disturbance characterized by motor immobility or excessive motor activity, mutism, negativism, posturing, stereotypies.

Prevalence: 10-15% of acute psychiatric inpatients; 20% of patients with schizophrenia experience catatonia at some point.

Etiology:

• Psychiatric: Schizophrenia, schizoaffective disorder, bipolar disorder (especially mania), severe depression
• Medical: Encephalitis (especially anti-NMDA receptor), metabolic (uremia, hepatic encephalopathy), neurological (Parkinson's, stroke), medications (antipsychotics → neuroleptic malignant syndrome differential)

Clinical Features (DSM-5: ≥3 of the following):

Assessment Tool: Bush-Francis Catatonia Rating Scale (BFCRS)—23 items, score ≥2 on screening section suggests catatonia.

Lorazepam Challenge Test:

• Give lorazepam 1-2mg IV/IM
• Reassess after 5 minutes and 10 minutes
• Positive response (improvement in catatonic symptoms within 10 minutes) confirms catatonia diagnosis
• Also therapeutic (see below)

Life-Threatening Forms:

Differential Diagnosis of Malignant Catatonia:

• Neuroleptic malignant syndrome: History of antipsychotic exposure; hyporeflexia; leukocytosis
• Serotonin syndrome: Recent SSRI/SNRI; hyperreflexia, clonus, mydriasis
• Encephalitis: Fever, headache, seizures, CSF pleocytosis
• Status epilepticus (non-convulsive): EEG shows seizure activity

Management:

1. Immediate (Life-Threatening Catatonia):

• Benzodiazepines:
  • Lorazepam 1-2mg IM/IV every 4-8 hours (first-line)
  • Titrate up to 8-24mg/day if needed
  • Response usually within hours to days (70-80% response rate)
• Supportive care:
  • IV fluids (often dehydrated)
  • Nutrition (NG tube if not eating)
  • VTE prophylaxis (immobility → high DVT/PE risk)
  • Skin care (pressure sores)
  • Monitor vital signs, temperature, CK

2. If Lorazepam Fails or Malignant Catatonia:

• ECT: Most effective treatment for catatonia (80-90% response) [see above]
• Bilateral, 2-3 sessions/week
• Often dramatic response after 1-2 sessions

3. Maintenance (After Acute Episode):

• Continue lorazepam, gradually taper over weeks to months
• Treat underlying psychiatric condition (antipsychotic for schizophrenia, mood stabilizer for bipolar)
  • "Caution: Reintroducing antipsychotics after catatonia carries NMS risk; start low dose atypical (quetiapine, clozapine)"
• Monitor for recurrence

Avoid:

• High-potency typical antipsychotics (worsen catatonia, risk NMS)
• Restraint (can worsen agitation, risk injury)

---

Psychosocial Interventions: Detailed Components

Cognitive Behavioral Therapy for Psychosis (CBTp)

Evidence base: NICE recommends CBTp for all patients with schizophrenia [24]. Meta-analyses show small-to-moderate effect size on positive symptoms, distress, and functioning [20].

Structure:

• Duration: 16-20 sessions (typically weekly, then fortnightly)
• Format: Individual therapy (group CBTp also effective)

Core Components:

1. Engagement and Assessment:

• Build therapeutic alliance (non-confrontational, collaborative)
• Functional analysis: How do symptoms impact daily life?
• Identify goals (reduce distress, improve functioning—not necessarily eliminate symptoms)

2. Psychoeducation:

• Normalize experiences ("Many people hear voices")
• Stress-vulnerability model (genetic predisposition + stress → psychosis)
• Treatment rationale

3. Cognitive Techniques (for Delusions):

• Socratic questioning: Gently explore evidence for/against beliefs
  • "What makes you think the government is monitoring you?"
  • "Are there other possible explanations?"
  • "Has there been a time when you thought this but it didn't happen?"
• Behavioral experiments: Test predictions arising from delusions
  • If patient believes "leaving the house will result in harm," plan graded exposure
• Generate alternative explanations: "Could there be another reason your neighbor looks at you?"
• Do NOT: Confront delusions directly ("That's not real")—increases defensiveness

4. Coping Strategies (for Hallucinations):

• Distraction: Music, conversation, exercise
• Engagement: Talk back to voices, set boundaries ("I'll listen to you for 5 minutes, then I'm going to ignore you")
• Focus: Attend fully to voices to reduce anxiety (paradoxical)
• Selective listening: Listen only to helpful voices, ignore critical ones
• Increase social contact: Isolation worsens hallucinations

5. Addressing Negative Symptoms and Social Functioning:

• Behavioral activation: Schedule pleasurable/meaningful activities
• Graded task assignment: Break goals into small steps (return to work → volunteer 2 hours/week → part-time → full-time)
• Social skills training: Role-play conversations, assertiveness

6. Relapse Prevention:

• Identify early warning signs (sleep disturbance, anxiety, increased suspiciousness)
• Develop coping plan ("If I notice warning signs, I will contact my care coordinator")
• Stress management

Outcomes:

• Reduces distress from persistent hallucinations/delusions
• Improves insight and treatment adherence
• Small effect on symptom frequency/intensity
• Improves functioning and quality of life

---

Family Intervention for Psychosis

Rationale: Family environment influences relapse risk. Expressed Emotion (EE)—criticism, hostility, over-involvement—predicts relapse (50-60% relapse at 9 months in high-EE families vs. 20-25% in low-EE).

Evidence: NICE recommends family intervention for all patients living with or in close contact with family [24]. Meta-analyses show 20-30% reduction in relapse.

Structure:

• Duration: 10-15 sessions over 6-9 months
• Format: Family meetings (patient + family members) with therapist

Core Components:

1. Psychoeducation:

• What is psychosis/schizophrenia?
• Causes (biological, not family's fault)
• Symptoms (positive, negative, cognitive)
• Treatment (medication, therapy, prognosis)
• Early warning signs of relapse

2. Communication Skills Training:

• Active listening (reflect, validate feelings)
• Expressing feelings using "I" statements ("I feel worried when you stay in your room all day" vs. "You're being lazy")
• Avoid criticism and blaming
• Set boundaries respectfully

3. Problem-Solving:

• Identify specific problems (e.g., patient refuses medication, sleeps all day, won't socialize)
• Brainstorm solutions collaboratively
• Agree on action plan, review progress

4. Reduce Expressed Emotion:

• Educate family that criticism/hostility worsen outcomes
• Help family understand that negative symptoms (lack of motivation, social withdrawal) are illness symptoms, not laziness
• Reduce over-involvement (excessive worrying, doing everything for patient—hinders autonomy)

5. Crisis Planning:

• Recognize early warning signs
• Who to contact (care coordinator, crisis team)
• When to go to Emergency Department

6. Support for Caregivers:

• Acknowledge caregiver burden
• Respite care, caregiver support groups (Rethink Mental Illness, Mind)
• Encourage self-care

Outcomes:

• Reduced relapse (20-30%)
• Improved medication adherence
• Better family relationships
• Reduced caregiver burden and distress

---

Vocational Rehabilitation: Individual Placement and Support (IPS)

Rationale: Employment is a strong predictor of recovery. Only 10-20% of people with schizophrenia are competitively employed (vs. 70% who want to work). Traditional "train-then-place" models (sheltered workshops → gradual transition) have poor outcomes.

IPS Model: "Place-then-train"—rapid job placement with ongoing support.

Principles:

1. Zero exclusion: Anyone who wants to work is eligible (no prerequisites like symptom stability, sobriety)
2. Rapid job search: Begin within 1 month of enrollment (no prolonged pre-vocational training)
3. Competitive employment: Goal is regular jobs in community (not sheltered workshops)
4. Integration with mental health care: IPS specialist embedded in clinical team, collaborates with psychiatrist/care coordinator
5. Follow patient preferences: Job search based on patient's interests and skills
6. Ongoing support: Time-unlimited support (not time-limited "job coaching")
7. Benefits counseling: Help navigate welfare system (fear of losing benefits is major barrier)

Evidence: Meta-analyses show IPS doubles competitive employment rates (55% vs. 25% with traditional vocational rehabilitation) [RCTs in schizophrenia].

Implementation:

• IPS employment specialist joins clinical team
• Assessment: What kind of work do you want? Past work experience? Barriers?
• Rapid job search: Develop relationships with employers, job matching
• Ongoing support: Regular workplace visits, problem-solving with employer/patient, accommodate symptoms (flexible hours, quiet workspace)

Outcomes:

• Higher employment rates
• Better quality of life and self-esteem
• No increase in symptom exacerbation or hospitalization (working does not worsen psychosis)

---

Peer Support and Self-Management

Peer Support Workers: Individuals with lived experience of mental illness employed to support others.

Roles:

• Share lived experience ("I've been there; recovery is possible")
• Model recovery, instill hope
• Support engagement with services, medication adherence
• Navigate systems (welfare, housing)

Evidence: Peer support improves hope, empowerment, engagement; mixed evidence on symptom reduction.

Self-Management Programs:

• Wellness Recovery Action Plan (WRAP): Patient-led program to identify triggers, early warning signs, coping strategies, crisis plan
• Supported self-management: Collaboration between patient and clinician to set goals, develop action plans

---

Social Prescribing

Definition: Linking patients to non-clinical community resources (arts, exercise, volunteering, social groups).

Examples:

• Art therapy, music therapy
• Exercise programs (yoga, walking groups)
• Gardening, volunteering
• Social clubs (reduce isolation)

Evidence: Limited high-quality RCT evidence, but growing interest; small studies show improved well-being, reduced loneliness.

---

Conclusion: Integrated, Recovery-Oriented Care

Modern treatment of psychosis is bio-psycho-social:

• Biological: Antipsychotic medication (manage positive symptoms, prevent relapse)
• Psychological: CBTp (reduce distress, improve coping), family intervention (reduce relapse)
• Social: IPS (employment), housing support, social prescribing (reduce isolation, improve QoL)

Recovery-oriented care emphasizes:

• Hope: Recovery is possible (20-30% full recovery, many more achieve meaningful lives)
• Patient autonomy: Shared decision-making, advance directives
• Holistic: Address physical health (metabolic syndrome, smoking, cardiovascular risk), social determinants (housing, poverty, discrimination)
• Strengths-based: Focus on abilities, interests, goals (not just symptoms)

Liaison with primary care: Patients with schizophrenia have 15-20 year reduced life expectancy, mostly due to physical health (cardiovascular disease, diabetes, smoking, obesity). Annual physical health checks are essential (UK: NHS Health Check for SMI).

---

Examination Scenarios (OSCE/Clinical)

Scenario 1: History Taking from Patient with Acute Psychosis

Candidate instructions: You are an FY2 doctor in the Emergency Department. A 24-year-old man has been brought in by police under Section 136 after threatening passersby. Take a focused psychiatric history. You have 10 minutes.

Approach:

1. Safety and Rapport (1-2 minutes):

• Introduce yourself, explain role
• Non-threatening posture (sit at angle, maintain distance, door accessible)
• Calm, respectful tone
• "I can see this has been a difficult time for you. I'd like to understand what's been happening so we can help."

2. Presenting Complaint and History of Presenting Illness (3-4 minutes):

• Open question: "Can you tell me what brought you here today?"
• Explore psychotic symptoms systematically (if patient guarded, adjust):
  • Hallucinations: "Do you hear sounds or voices when no one is around?"
  • Delusions: "Do you feel unsafe? Is anyone trying to harm you?"
  • "Thought disorder: Assess from spontaneous speech"
• Timeline: "When did this start?"
• Precipitants: "Did anything stressful happen before this began?"

3. Risk Assessment (2-3 minutes—CRITICAL):

• Suicidal ideation: "Have you had thoughts of harming yourself?"
• Homicidal ideation: "Have you thought about harming anyone else? Do the voices tell you to hurt people?"
• Vulnerability: "Are you able to look after yourself? Eating, drinking, staying safe?"

4. Past Psychiatric History (1 minute):

• "Have you had anything like this before?"
• Previous diagnoses, hospitalizations, treatment

5. Substance Use (1 minute):

• "Do you use any drugs like cannabis, cocaine?" (non-judgmental tone)
• Alcohol

6. Collateral History (if time):

• "Is there someone who knows you well that we could speak to?"

Key OSCE skills:

• Non-confrontational: Do NOT challenge delusions ("That's not real")
• Direct questions about risk: Examiners want to see you ask explicitly about suicide, violence
• Safety awareness: Position yourself near door, remain calm

Examiner's mark scheme:

• Rapport and communication (respectful, empathetic)
• Systematic assessment of psychotic symptoms
• Risk assessment (ask about suicide, violence, self-neglect)
• Appropriate use of open and closed questions
• Recognition of need for collateral history

---

Scenario 2: Mental State Examination (Observed)

Candidate instructions: Perform a mental state examination on a 30-year-old woman admitted to the psychiatric ward with first-episode psychosis. Present your findings. You have 10 minutes.

Structure (use headings, present systematically):

1. Appearance and Behavior:

• "The patient is a casually dressed 30-year-old woman who appears her stated age. She has poor eye contact and sits in a guarded posture. Psychomotor activity is within normal limits. She is cooperative but appears suspicious."

2. Speech:

• "Speech is spontaneous, normal rate and volume. There is evidence of formal thought disorder, specifically tangentiality—answers veer away from the question."

3. Mood and Affect:

• "Subjective mood: She reports feeling 'confused.' Objective affect is blunted (reduced range). Affect is congruent with mood."

4. Thought Form:

• "Formal thought disorder is present, as described above (tangentiality). No flight of ideas, thought blocking, or neologisms noted."

5. Thought Content:

• "The patient expresses persecutory delusions, stating that her neighbors are 'spying on her through the walls.' She believes they can hear her thoughts (thought broadcasting). Delusions are held with strong conviction and are not amenable to counter-evidence. No suicidal or homicidal ideation expressed today."

6. Perception:

• "The patient reports third-person auditory hallucinations—two voices discussing her ('She's paranoid,' 'Leave her alone'). She also reports command hallucinations telling her to 'stay indoors for safety.' No visual, tactile, or olfactory hallucinations."

7. Cognition:

• "The patient is alert and oriented to person, place, and time. Attention and concentration appear grossly intact. No formal cognitive testing performed during this interview."

8. Insight and Judgment:

• "Insight is partial—she acknowledges she is in hospital but attributes her experiences to external forces ('the neighbors') rather than illness. She is ambivalent about medication."

Examiner's mark scheme:

• Systematic presentation using MSE headings
• Accurate use of psychiatric terminology (tangentiality, delusions, hallucinations)
• Distinction between subjective mood (patient's words) and objective affect (your observation)
• Assessment of insight
• Professional, concise delivery

---

Scenario 3: Explaining Diagnosis to Patient/Family

Candidate instructions: You are an ST4 in psychiatry. Explain the diagnosis of schizophrenia to a 22-year-old man who has just had his first psychotic episode. His mother is present. You have 10 minutes.

Approach:

1. Set the Scene (1 minute):

• Private, quiet room
• Introduce yourself
• "I'd like to talk to you about what's been happening and discuss the diagnosis we think fits best."
• Check understanding: "What have you been told so far?"

2. Deliver Diagnosis (2 minutes):

• Use simple language: "Based on your symptoms—hearing voices, believing you were being followed—we think you have a condition called schizophrenia."
• Normalize: "Schizophrenia is a medical condition that affects how the brain processes information. About 1 in 100 people experience it."
• Avoid: Stigmatizing language ("mental illness means you're crazy"), jargon ("psychotic disorder NOS")

3. Explain Symptoms (2-3 minutes):

• Positive symptoms: "Experiences like hearing voices or having unusual beliefs are called positive symptoms—they're additions to normal experience."
• Negative symptoms: "Some people also have negative symptoms—less motivation, difficulty experiencing pleasure. These can be harder to treat."
• Cognitive symptoms: "Concentration and memory can be affected."

4. Explain Treatment (2-3 minutes):

• Medication: "We use medication called antipsychotics to reduce the voices and unusual beliefs. They work by adjusting brain chemicals. Side effects can include weight gain, drowsiness—we'll monitor this closely."
• Talking therapy: "Therapy can help you manage distressing symptoms and cope better."
• Support services: "Our Early Intervention team will work with you for 3 years, helping with medication, therapy, education, and work."

5. Prognosis (1-2 minutes):

• Realistic but hopeful: "With treatment, many people recover fully or manage symptoms well and lead fulfilling lives. About 1 in 5 people recover completely. Early treatment improves outcomes—this is why starting medication now is important."
• Be honest: "Schizophrenia can be a long-term condition, and some people have relapses, but ongoing support reduces this risk."

6. Address Concerns (1-2 minutes):

• "What questions do you have?"
• Common concerns:
  • "Will I be like this forever?" "With treatment, symptoms improve. Some people recover fully, many others manage well."
  • "Did I cause this?" "No, schizophrenia is a medical condition caused by brain chemistry, genetics, and stress—it's not your fault."
  • "Will medication change my personality?" "Medication reduces symptoms like voices and paranoia. It doesn't change who you are."

7. Follow-Up Plan:

• "Our team will see you weekly initially. Here's a contact number if you have concerns."

Examiner's mark scheme:

• Clear, jargon-free language
• Empathy and sensitivity (avoid stigma)
• Balanced prognosis (realistic but hopeful)
• Opportunity for patient/family to ask questions
• Follow-up plan and ongoing support emphasized

---

Differential Diagnoses: Key Distinctions

Psychosis vs. Delirium

Clinical pearl: If consciousness is impaired or attention cannot be sustained, it is delirium until proven otherwise—investigate medical causes urgently.

Cannabis-Induced Psychosis vs. Primary Psychotic Disorder

• Temporal relationship: Symptoms begin during/after cannabis use; resolve within days-weeks of abstinence (though can persist)
• Content: Cannabis-induced psychosis often features paranoia, visual hallucinations (less common in schizophrenia)
• Longitudinal course: True schizophrenia persists despite prolonged abstinence
• Challenge: Cannabis use is highly prevalent in FEP; difficult to distinguish initially; prolonged observation after abstinence required [6]

Schizophrenia vs. Schizoaffective Disorder

• Schizoaffective: Major mood episode (depression or mania) concurrent with psychotic symptoms AND psychosis present for ≥2 weeks without mood symptoms
• Schizophrenia: Psychosis dominates; mood symptoms if present are brief relative to psychosis
• Diagnostic challenge: Often requires longitudinal observation; initial diagnosis may be revised

---

Patient and Family Education

What is Psychosis?

Psychosis is a condition where a person loses touch with reality. This can include:

• Hearing voices that others do not hear
• Believing things that are not true (such as being followed or monitored)
• Confused thinking or difficulty organizing thoughts
• Withdrawal from friends, family, and activities

Is Psychosis Treatable?

Yes. With early treatment (medication and psychological therapies), many people recover or manage symptoms effectively. Early treatment is critical—the sooner treatment starts, the better the outcomes.

What Causes Psychosis?

Psychosis results from complex interactions between:

• Brain chemistry (dopamine, glutamate)
• Genetic factors (family history increases risk)
• Stress (life events, trauma)
• Substance use (cannabis, stimulants)

It is not caused by personal weakness or poor parenting.

Treatment

1. Medication (antipsychotics): Reduce hallucinations, delusions, and disorganized thinking
2. Talking therapies: Cognitive Behavioral Therapy for Psychosis (CBTp) helps manage distressing symptoms
3. Family support: Family therapy improves outcomes and supports caregivers
4. Practical support: Help with education, work, housing, social activities

What Can Families Do?

• Learn about psychosis: Understanding the illness reduces fear and stigma
• Encourage treatment: Support medication adherence and therapy attendance
• Recognize warning signs: Early relapse signs include sleep disturbance, anxiety, social withdrawal
• Reduce stress: Calm, supportive home environment; avoid criticism or over-involvement
• Look after yourself: Caregiving is demanding; seek support (e.g., Rethink Mental Illness, Mind)

Substance Use

• Cannabis, cocaine, amphetamines worsen psychosis and reduce treatment effectiveness
• Stopping substance use is one of the most important steps toward recovery

Resources

• Rethink Mental Illness: www.rethink.org (UK-based support for psychosis)
• Mind: www.mind.org.uk
• Early Intervention in Psychosis (EIP) services: Specialist NHS teams for first-episode psychosis
• SANE: www.sane.org.uk (mental health helpline and support)
• Hearing Voices Network: www.hearing-voices.org (peer support for voice-hearers)

---

Evidence and Guidelines

Key Guidelines

1. NICE NG43: Psychosis and Schizophrenia in Adults (2014) — Comprehensive guidance on assessment, treatment (pharmacological and psychological), and service delivery [24]
2. NICE CG178: Psychosis and Schizophrenia in Children and Young People (2013) — Pediatric and adolescent FEP
3. British Association for Psychopharmacology (BAP): Evidence-based Guidelines for the Pharmacological Management of Schizophrenia (2019) — Detailed antipsychotic prescribing guidance
4. Royal College of Psychiatrists: Early Intervention in Psychosis Services — Service standards and pathways

Landmark Trials and Evidence

Early Intervention in Psychosis (EIP):

• OPUS trial (Denmark): EIP services (intensive case management + family therapy + social skills training) vs. standard care → 20% reduction in positive/negative symptoms at 2 years [19]

Antipsychotic Efficacy:

• CATIE trial (USA): Large pragmatic trial comparing first-generation and second-generation antipsychotics → olanzapine slightly superior efficacy but higher metabolic side effects; no single agent clearly superior [16]
• CUtLASS trials (UK): First-generation vs. second-generation antipsychotics → no significant difference in symptom control or quality of life (challenged superiority of atypicals)

Clozapine:

• Cochrane review: Clozapine more effective than other antipsychotics for treatment-resistant schizophrenia (30-50% response rate vs. 10-20% with other agents) [17]
• InterSePT trial: Clozapine reduces suicide risk by 25% vs. olanzapine in high-risk patients

Duration of Untreated Psychosis (DUP):

• Meta-analyses: DUP consistently associated with poorer outcomes (symptom severity, functional outcomes, negative symptoms); every month of DUP correlates with worse prognosis [21]

Cannabis and Psychosis:

• Meta-analysis (Di Forti et al., Lancet Psychiatry 2019): Daily high-potency cannabis use increases odds of psychotic disorder 5-fold; 20% of FEP cases attributable to high-potency cannabis use [6]

Cognitive Behavioral Therapy for Psychosis (CBTp):

• NICE meta-analysis: CBTp reduces distress from persistent hallucinations/delusions, improves functioning; small-to-moderate effect sizes [20]

---

Summary: Key Take-Home Points

1. Acute psychotic episode is a psychiatric emergency requiring urgent assessment, risk management, and exclusion of organic causes (delirium, encephalitis, metabolic, substance-induced).

2. Positive symptoms (hallucinations, delusions, disorganized speech/behavior) respond to antipsychotics; negative symptoms (flat affect, alogia, avolition) are more treatment-resistant and predict functional impairment.

3. Differential diagnosis includes schizophrenia, brief psychotic disorder, schizoaffective disorder, substance-induced psychosis, and organic causes (autoimmune encephalitis, delirium, CNS lesions).

4. Medical workup is mandatory: FBC, U&E, LFTs, TFTs, glucose, calcium, B12, syphilis serology, HIV, urine drug screen; brain imaging and LP if clinically indicated.

5. First-line antipsychotics for first-episode psychosis: risperidone, olanzapine, aripiprazole (avoid haloperidol—higher EPS risk, poorer tolerability).

6. Duration of Untreated Psychosis (DUP) is a critical prognostic factor—shorter DUP (less than 3 months) associated with better outcomes. Urgent psychiatric referral to Early Intervention in Psychosis (EIP) services is essential.

7. Risk assessment must address suicide (10-15% lifetime risk), violence (especially command hallucinations, paranoid delusions), and vulnerability (self-neglect, exploitation).

8. Mental Health Act assessment may be required if patient lacks capacity and poses risk to self/others.

9. Early Intervention in Psychosis (EIP) services provide 3 years of intensive case management, CBTp, family intervention, and vocational support—improve outcomes and reduce relapse.

10. Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia (failure of ≥2 antipsychotics) but requires weekly FBC monitoring (agranulocytosis risk).

11. Substance use (cannabis, stimulants) worsens psychosis, increases relapse, and reduces treatment response—abstinence is critical.

12. Prognosis: 40-50% achieve symptomatic remission at 1 year; 20-30% achieve full recovery long-term; suicide risk 10-15% lifetime.

---

References

1. Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195-1203. PMID: 30053165

2. Kirkbride JB, Errazuriz A, Croudace TJ, et al. Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS One. 2012;7(3):e31660. PMID: 22457710

3. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19-28. PMID: 17199051

4. Selten JP, van der Ven E, Rutten BP, Cantor-Graae E. The social defeat hypothesis of schizophrenia: an update. Schizophr Bull. 2013;39(6):1180-1186. PMID: 24062592

5. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421-427. PMID: 25056061

6. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427-436. PMID: 30902669

7. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull. 2009;35(3):549-562. PMID: 19325164

8. Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012;38(5):920-926. PMID: 22987850

9. van Erp TGM, Walton E, Hibar DP, et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biol Psychiatry. 2018;84(9):644-654. PMID: 29960671

10. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36. PMID: 17262855

11. Fett AK, Viechtbauer W, Dominguez MD, et al. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2011;35(3):573-588. PMID: 20620163

12. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220-229. PMID: 22393215

13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013.

14. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247-253. PMID: 15753237

15. National Institute for Health and Care Excellence (NICE). Violence and Aggression: Short-Term Management in Mental Health, Health and Community Settings (NG10). 2015. Available at: www.nice.org.uk/guidance/ng10

16. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia (CATIE). N Engl J Med. 2005;353(12):1209-1223. PMID: 16172203

17. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385-392. PMID: 27491532

18. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957-965. PMID: 24229745

19. Bertelsen M, Jeppesen P, Petersen L, et al. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry. 2008;65(7):762-771. PMID: 18606949

20. Jauhar S, McKenna PJ, Radua J, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014;204(1):20-29. PMID: 24385461

21. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785-1804. PMID: 16199825

22. Lally J, Ajnakina O, Stubbs B, et al. Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. Br J Psychiatry. 2017;211(6):350-358. PMID: 28982659

23. Hunt GE, Large MM, Cleary M, et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234-258. PMID: 30153621

24. National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Prevention and Management (CG178). 2014 (updated 2020). Available at: www.nice.org.uk/guidance/cg178

25. Drake RJ, Haley CJ, Akhtar S, Lewis SW. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry. 2000;177:511-515. PMID: 11102325

26. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. PMID: 23810019

27. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91. PMID: 12511175

---

Document Version: 1.0 (2026-01-09)
Next Review: 2027-01-09
Evidence Quality: High (27 PubMed-indexed citations)
Target Audience: Psychiatry trainees (MRCPsych), Emergency Medicine, Acute Medicine physicians
Estimated Reading Time: 35-40 minutes (comprehensive review)